14 results about "Thrombo embolism" patented technology

The invention relates to the technical field of health monitoring, in particular to venous thromboembolism monitoring equipment which comprises an evaluation module used for providing an evaluation scale, collecting filling information of a patient and generating a risk level evaluation result; the behavior guidance module is used for generating corresponding guidance suggestions based on the risk level assessment result, so that the patient can be protected according to the guidance suggestions; the monitoring module is used for collecting monitoring data in the protection process of the patient according to the guidance suggestions, and the monitoring data comprise leg circumference data, pain feeling data, skin color data, body temperature data, limb swelling data and pulmonary embolism expression data; and the early warning module is used for generating early warning information based on the monitoring data, and sending the early warning information to related medical personnel, so that manual monitoring is replaced by the monitoring equipment, the self-protection consciousness of the patient can be autonomously stimulated, the monitoring effect is improved, and the morbidity of venous thromboembolism is reduced.

A method for the treatment of thromboembolism comprising administering a thrombolytic agent directly to the thromboembolism in the presence of ultrasound. The total dose of thrombolytic agent administered is between 1 and 12 mg and the time over which the total dose is delivered is less than 15 hours.

The invention provides a thrombus prevention method and system based on digital clinical precise execution, and relates to the technical field of digital medical treatment, and the method comprises the steps: obtaining clinical data of a patient, and determining a thromboembolism risk level, a bleeding risk level and a mechanical prevention taboo state of the patient based on a preset rule; based on the combined state of the three evaluation results, generating a thrombus prevention measure scheme for the patient through a preset prevention strategy decision rule; monitoring clinical data changes in the hospitalization process of the patient in real time, when it is detected that the risk level or the taboo state is changed, comparing the consistency of a current execution scheme with a scheme regenerated based on the changed state, and if the current execution scheme is not consistent with the scheme regenerated based on the changed state, generating preventive measure adjustment reminding information; and pushing the scheme or the adjustment prompt to a clinical medical care terminal. According to the invention, intelligent decision and dynamic adjustment of thrombus prevention can be realized, the accuracy and timeliness of prevention measures are improved, and medical risks are reduced.

Novel direct thrombin inhibitors are provided herein, along with methods for their use as anticoagulants. The direct thrombin inhibitors described herein are useful in treating and / or preventing thromboembolism and bleeding or clotting disorders. Also provided herein are methods for inhibiting thrombin in a cell using the compounds and compositions described herein.

The present invention relates to a pyrazol[3,4 c] pyridine derivative, preparation method and use in medicine thereof. Specifically, the present invention relates to a novel pyrazol[3,4 c] pyridine derivative, preparation method thereof and a pharmaceutical composition comprising the derivative and use thereof as a therapeutic agent, especially their use as Xa factor inhibitors and in the preparation of drugs for treating diseases like thromboembolism.

The invention discloses a medicine for treating atrial fibrillation in an acute exacerbation stage of a chronic obstructive pulmonary disease and a preparation method of the medicine. The medicine is prepared from raw rhizoma coptidis, raw fructus gardeniae, lophatherum gracile, radix ophiopogonis, radix rehmanniae recen, lily, codonopsis pilosula, radix salviae miltiorrhizae, moutan bark, radix paeoniae rubra, semen boitae, spina date seeds, poria with hostwood and raw liquorice. The traditional Chinese medicine composition has the effects of clearing away heart fire and nourishing heart yin, has the effects of cooling and activating blood and clearing away heart fire and tranquilizing mind, and is suitable for atrial fibrillation in the acute exacerbation stage of chronic obstructive pulmonary disease, assisting in controlling the ventricular rate, preventing and treating thromboembolism and promoting the atrial fibrillation rhythm to be converted into sinus normal rhythm.

A medical device is provided in which one or both ends of the device encourage the formation of tissue across substantially the entire area of the respective end that is exposed to the blood flow for reducing the risk of a thrombotic embolism. The medical device includes a tubular structure having at least one expanded volume portion and a tapered transition portion. The tubular structure may be made through the braiding of a number of strands, and a first end feature may be used to secure the proximal strand ends. The proximal strand ends may be secured via the proximal end of the first end feature, such that the tapered transition portion is formed over the circumferential surface of the first end feature, and only a proximal end surface (or a portion of the proximal end surface) of the first end feature is exposed to the path of flowing blood.

The present invention relates to novel sustained release formulation of milvexian, which are useful for the treatment or prevention of thromboembolic events. The invention is particularly suitable for once-a-day administration of milvexian, releasing a therapeutically effective amount of the milvexian over an extended time.

A medical device is provided in which one or both ends of the device encourage the formation of tissue across substantially the entire area of the respective end that is exposed to the blood flow for reducing the risk of a thrombotic embolism. The medical device includes a tubular structure having at least one expanded volume portion and a tapered transition portion. The tubular structure may be made through the braiding of a number of strands, and a first end feature may be used to secure the proximal strand ends. The proximal strand ends may be secured via the proximal end of the first end feature, such that the tapered transition portion is formed over the circumferential surface of the first end feature, and only a proximal end surface (or a portion of the proximal end surface) of the first end feature is exposed to the path of flowing blood.

A computer-implemented system (CIS) is provided for processing and / or analyzing non-contrast-enhance computer tomography medical imaging input data is described. The CIS contains (i) twin U-Net architectures with equal weights, which are built on a Siamese architecture, and (ii) a Dissimilar block operably linked to the two U-Net architectures, and built on top of the Siamese-U-Net architecture to form a Dissimilar-Siamese-U-Net architecture. The computer-implemented system can be used in diagnosing acute ischemic stroke and / or thromoboembolus, by analyzing separate and independent input images of the left and right hemispheres of a brain. The diagnosis is based on a detection of the presence of a hyperdense middle cerebral artery sign.

This invention relates to the field of intelligent medical data analysis technology, specifically to a method and system for the intelligent prevention and control of venous thromboembolism in hospitalized patients. The method involves acquiring static medical record features and determining target test indicators; determining the target time window through a closed-loop adaptive mechanism driven by the fitting uncertainty of a Gaussian process regression model; constructing a weighted bipartite graph and removing confounding factors based on the topological overlap of pathological pathways to extract pure thrombosis baseline scores and pure bleeding baseline scores; extracting the first and second derivatives of time-series data and concatenating them with the pure baseline scores to construct a dynamic feature vector; generating a baseline-driven adaptive boundary in a two-dimensional phase plane; constructing a short-range predicted trajectory based on Taylor expansion and solving for the collision time; performing multi-objective game arbitration based on the time priority principle to generate prevention and control strategies; and achieving forward-looking joint decision-making in a dynamic conflicting scenario of thrombosis and bleeding risks.

The present invention provides a pharmaceutical composition containing ticagrelor for use in reducing or preventing thromboembolic events before and / or during and / or after neurovascular arterial procedures in a patient requiring the use of the pharmaceutical composition containing ticagrelor, comprising administering an effective amount of the pharmaceutical composition containing ticagrelor to a patient, wherein the pharmaceutical composition is an aqueous solution containing a solubilizing agent for ticagrelor and the pharmaceutical composition is administered intravenously; wherein the patient suffers from a cerebral aneurysm, cerebral arteriosclerosis, cervical arteriosclerosis, neurovascular carotid dissection or carotid dissection.